Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people taking Wegovy notice changes around their neck, shoulders or upper back, and want to understand whether the medicine is involved. The short answer is: neck-related changes during Wegovy treatment are usually connected to rapid fat loss rather than a direct drug effect, though any new or persistent neck symptom warrants a clinical conversation. Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK for weight management in adults, and like any prescription medicine it must be assessed by a qualified prescriber before you start. The NHS's guidance on semaglutide covers the known side-effect profile in full, and neck-specific changes are not listed among them — which is worth knowing from the outset.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Significant weight loss (the kind that clinical trials of Wegovy consistently produced) doesn't happen uniformly across the body. Fat is shed from different regions at different rates, and the neck, chin and upper chest are areas where many people first notice visible change. In the STEP 1 trial, participants on 2.4 mg semaglutide lost an average of roughly 15% of body weight over 68 weeks, as published in the New England Journal of Medicine. Losing that proportion of body weight in under two years can leave skin in the neck and jaw area less supported than before, especially in adults whose skin elasticity has reduced with age.
This is a mechanical consequence of fat loss, not a pharmacological one. Semaglutide doesn't target neck tissue specifically; it reduces appetite and slows gastric emptying, leading to an overall calorie deficit, and our page on semaglutide and the neck explores in more detail how these changes tend to present. Some people are delighted by the change. Others find that looser skin or a changed silhouette around the neck and shoulders takes adjustment. Both responses are completely understandable.
If you want to read more about the broader range of skin-related changes people report during weight-loss treatment, our page on neck skin changes with Wegovy goes into this in more detail.
Neck pain and stiffness are not listed as known side effects of semaglutide in the UK prescribing information. The established side-effect profile is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation and reflux are the most common, particularly in the weeks after a dose increase. Fatigue and headache also appear with some regularity. Musculoskeletal complaints in the neck specifically are not a recognised pattern.
That said, two indirect mechanisms are plausible. First, posture can shift during rapid weight loss as the body's centre of gravity changes and people become more physically active after years of carrying higher body weight. Second, dehydration from persistent nausea or reduced fluid intake (a real risk if GI symptoms are troublesome) can cause muscle cramping more broadly, including around the shoulders and neck. Staying well hydrated matters on this treatment, and it's worth discussing with your prescriber if GI symptoms are making that difficult.
Anyone experiencing significant or worsening neck stiffness alongside other symptoms should seek medical advice. Our page on stiff neck and Wegovy covers this in more detail, including when to contact a GP or call 111 without delay.
Most neck changes during Wegovy treatment are benign and related to fat redistribution or skin changes. A few, however, need proper clinical assessment and shouldn't be waved away.
Seek prompt medical review if you notice: a new lump or swelling that wasn't there before treatment; pain that isn't improving after a few days; swelling that feels firm rather than soft; difficulty swallowing or any change in your voice; or a general feeling of illness alongside the neck change. These symptoms are unlikely to be related to Wegovy, but because they can occasionally signal something else, they deserve eyes-on attention from a clinician rather than reassurance from an article.
The standard advice from NHS England's guidance on weight-management injections is to keep your prescribing team informed of new physical symptoms as they arise. At nume, that access is built into the service: our information on check-ups during Wegovy treatment explains how ongoing clinical oversight works in practice. If you have concerns between planned reviews, our support team is available seven days a week and can escalate to a prescriber where needed.
One practical note: if you're starting treatment or due a dose review around a busy stretch (a bank holiday, a holiday abroad, or simply payday week when you're planning your next order) it's worth building in a little extra time for your clinical review rather than rushing. Same-day dispatch is available Monday to Friday, but prescribers need the full picture before any increase is signed off.
For a broader overview of what's currently known about semaglutide as a treatment, our Wegovy overview page covers the full licensed picture, from how it works to what the evidence says about results. If you're weighing up treatment options or want to understand your eligibility, our weight-loss treatment page is a good starting point before any consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.